Drug intelligence / Profile preview

MVA-HPV

Development stage: Phase 2
Lead developer: Barinthus Biotherapeutics
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MVA-HPV is a Modified Vaccinia Ankara (MVA)-vectored multigenotype high-risk Human Papillomavirus (hrHPV) vaccine. Developed by Barinthus Biotherapeutics, it is being investigated as a trial vaccine for its safety, tolerability, and immunogenicity in women with low-grade HPV-related cervical lesions. It is designed to induce an immune response against multiple genotypes of hrHPV.

Beyond the preview

Go deeper on MVA-HPV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVA-HPV.

Explore the full profile